Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.

ABSTRACT:

Importance

Erythrodermic atopic dermatitis (AD) is a severe AD subtype defined by extensive skin involvement, leading to complications and sometimes hospitalization.

Objective

To assess dupilumab's efficacy and safety in patients with erythrodermic AD in clinical trials.

Design, setting, and participants

This post hoc analysis included patients enrolled in 6 multicenter, multinational, randomized, double-blind, placebo-controlled trials. Patients included in this analysis met erythrodermic AD criteria of 90% or greater body surface area (BSA) affected by AD and Global Individual Sign Score for erythema of 1 or higher. Data analyses for this post hoc analysis were conducted between March 5, 2019, and October 24, 2020.

Interventions

Dupilumab once weekly or every

SUBMITTER: Paller AS 

PROVIDER: S-EPMC10018319 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature